DOCSLIB.ORG

Designer Drugs.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Designer Drugs.Pdf Designerdrugs, *",,ird., "". nnf\ drl(Jt\).i.\ {rn! druA\rllrnrdr I drr eite.c ft .l.$i. m,..rir\, dm Lt.rr- ., lriLnriffgfr. Ll\ nightLr .,lrd,ng lhr .h.nj.rr {n,.rr( of .\ + n! !rrr!!, b,r.l mrrllr ".lr!nlnG' rrdrc n.r' d.risnf/' dI g\ m ,,i ,nllnfr rr ,r\! (1 prosr(rtnin nn il{,tiL.l,rF i,ir rlii! rhrInrlrr.r f.trjLi.r \\nilr.ri.rrlLr$ ,hl.1,,t)f..it rd rnd JsrLbur.dts.nmrrlir r !\. Trr lrm',n$itn.r J,!f :r i.,r n\r$tr.,l {rl[t.rrr .Rl li.r!h r,Li.rt.lr 5kl. rir.d- r\r l|tf rijrl,f lnJLr-rhrn.i| .,irf..r Ii r,. r nfr.Jrlrb.Drliir & r(\tr!fi ..1. i lr,r!\ \ \,! Li(rr! !!,t!l ,r: rrun .i rLlr rinf\ i f fi.\rf !Lrhri Lr n'rrfrr!l liLrrl nr.n!.r oLh.r rij r!\ n!,! ti,\.t fr rrf l.rnr fr nrrf. rr r. \'if .,N- blrnrD J rD+nin. frLr{al\rrir l rhi.h .i!\!i lin,, rr .,nrllir n,rrrrr sr np rinl Ll. l.r [ir].x! Lr!,x. orr, f:fti !rr r! . r \ rnhfr )r lli!\: 'fr !, fi!r.t ni \ I tr r,rtu{ rnfrn ir ..rL- n{ rf r\ rr. !l.fd.LfiJi\\fi!ri\\ r,,.i"rr.i{ lr.ltnr.,rlr.fnr \tlr\l\\1D\r\ WhotAre The Side Effecrs Of ueSrgner I r\t f\ (, thf .\P.!lLr{ rrnb.r .j nfr 'r$i!n., d,!:r' l.l i!.,f.i.f r i. (.ft o I 5r[.r.]n!r\ ,\.r \r! r)fii.,r I rli llr \lr.\ \i!- !N !iruq\.al,l!hi\ ,rl!1,.t\r Srn ( nn 1,l.\1 srLj{.Nrr \n,,fsLf lni.n.n.rr .inn\.\f. .nL.n : L \inirr fr rrrr tntrn.f ,\n.r rrsi r i - \l tr,,rlr l ilte!.n [)n].rn'.rf rr L]l..ritirri lirnrLf n.nrrn,.' r.rln tr' .. iL ., tn.-r\. rlr.irr.,l, ,\l,r!h ,,tu .uL. !i,r,g.x u!rd ni n..rtr. rll. J.- fnr.l]L i q.hdL n.nnrrlLl {n l.r trr rf r . ffuiritiir ,n, r : r\ t\qL. lf,frir!l n&!h r \trtrr] . \, (.rr, \.rriltrg, JiitrLrl . rr rrlL[ ini] r. N\Jrr l(f,i('\ ![ftu$.f n+P,r,. rnd r. u, \ lnr !l rt l.rnd Lln.n r .n . Contrri.ni Lninr . r.l:t+tri r, f.rrn.r WhotAre TheHozords Of . \0fnr ,,ilfi,i tjrl,rrr Designer ' l\.{f.f n,u!-r,rmJrrnL,., L'\ uifrl Seizures,Coma.lnd Death! l]nr itr ".i.ifn. rirr lillr.f rr ltl i iL\ ' llr!tr.\ 1r,,r-\ llr \,. \[{rr]tr nl Well-known DesignerDrugs Early n.r.oti. analogs(rentanyl and mep€ndine-based): . AMF,or 'ChinaWhit. .n rhe Tryptamine-bas.d(h.ltu.iq4r no- Daryrrcus subtalle knawn colledively.s'tlub .lrWJ Fler ro a wide vaneryof Phen€thylamin.-basedGtimu, dtrgs .onmoly Nd by individuais in : paily,likr atuosphcr. lanr, hallDcinogenicprcperti€s) oub druas d be iound,r nisii club, baD cone6 and nv6 d rane evenb. Rive and bare €venb aF all n*ht dan@sheld in s€at plae, suchas waEh@$ .2C T 7 ("7thrleavft") 6. Many prrty-aeB do nor u* dtu3s,bur $k wlrc do nay be aua&d io d'e low ct, inroxi.atina pR . DOB hichs, and suppos€din@as in shnin. ud oI felinS rhai . VBDB A@rditi ta NIDA, CHB,Rahtttol, K*rn"n , E*trsy, HetuntE6tns? . MDE o M4tempkbnlin nnd LsD a4 n tdtS thzdmss rfd blt k nry6 Md rdrft. uln m .lvIDEA . IVIDNIA . MMDA nT] WhqlAre lhe uqnger5t PcP-based(haUu.inogenic Although !se6 frav lhink of .lub .lrugs as harml.*, indi!idual Fac ti.ns trre unFrdictablc. Research 'TCP showsIhat cllb dtugs..n prcdu.ea ' PCE rLidc ranSe of unwintrd rffe.r!, in.n'ding hallucifalions, p.ranoia, elen fital r.r.rions lhe lirst rimc cLub dn'g\ iro use,l l,arlygoers iho usc dub druBsma! erperimdnt Nith . variciy of dru8s at one tine, ch'b drug u*r! $ rhe la.t that lh. CBL boih r pPcuFor or .onbinc a dru8 uilh al.ohol. toxicitt and sidc effedr are unpre Combinnrgdn'gs and ik.holinten diciable dle to unc.nituirs rbour sifipsad\€6e elfc.t! rnd cr.trtesan Lhcsourcer chemjcah,.nrtconrimi- . l,r Butanediolanother CHB clen noE dang.ou\ and nnPre narcs u\cd in nanulachfing th. di.tible Esull. A.oth.r dangor for luPPlenenis tor bodybu,ldinS, Ial GHB loss,rcrc$al of bnldncs\,dcprcslion and many other conditions CHB Commonly Eletred to as "date analogs3redisirlbuted as.lear.o1or rapedrugr" CHB, Ketamineand lc\s liquids rnd aPconsunEd ora l Rohypnol ar .€nhal nenous sye CIIB analogsacaddi.tile and .ausc lem dePr€ssmts.In liquid fod, synPlons similarto lhat ofGllB rhey are olten odorless,colorle$, lasleless,and can be added into an Ketomine unsuspectingperson's drink Tle dng incapa.itatesrho vi.iim rnd plevenls them fom resisting monlr lsed nr dtugjacjlilatedFxual assault The Yi.tim can suffer Jssauks.CHB (gamnrahydroxtbu "amnesi4'and may not rnen- t_rhtd)is rbusedror its euphoricand ber events expeiien.€d whil€ Pow.rtul scdative effecis. sheer mder the eilects ol the dtug. If nnnos in.ludc "liquid e.\tisl,, ' "easl, you attendparlies. nightchbs, oi lay,' vita-C,' and "Ceo.gii h.mr hequdt placeswiih largecowds, bo)r"CHB is usuallvtaken orallv in be awarethat sone dihinal! u* huid forn, arthouShcrPsure and drugs to incapacitateboth nen labletfom is rvailablc.A poudcrcd and womennot onlt for the pu. lolm ol cHB c.n be snorled.Lnluid K" or "ritamnrK a.d is sonetimcs pop df s€xualassauli, bui also for CHB is saltytasling and is lypicalli sold u.der the name eslist.' ohertriminal actssu.h asmbbery Found in eirher Po{der or tiqlid rom, it canbc snortcdor injcct.d. Co'nmon loR dose eilectsinclude DRUGNNDUCEDRAPE frlrxationsimrltrr to alcoholNorica Ketaminecreaies efae.is sinrilar ro PREVENTIONAND tion, euPhoia,rcdu.cd inhibitiont lho\sof PCPoroiher hallucinoge.s. PUNIsHMENI A(T OF I996 and in.re.sed scnsorystimulation. Users may experien.. drrad-likt Higherdoses lead to sludedsp&ch, stalesandh.lhcinations Low doss This federalstahte provideslor inlomn'a,sNealing, a8ilation,.on ol Kerani'reprcdu.e . rel.xedfeel p€nalhes up to Menty yea6 in b.tivcncss,.onfusion, toss .f c@rdr irg a Plerlani \{eiahrlesmessr,r prison for the intent t. rcnnii a nation, seizurdt rusPn.tor! dcprcr high doses,K.iaminc cin causcl crimeof violenc (includjnB*rual sion,uri'raN and fecalincontinen.e, reelifgof separationlron lhe bod\t assault)aSainsr an individualby Y.mirin8,.onra afd dealrr mpaircd motor dishibutionof a Nntolled sub function, high blood pressure, ps stde to that individualwithoui CI{B is pruduccdillogJlly though dcprussion,and potcnhillybtal one pres(iption lorm of cHB, pnitort problrms. Likc MDMA, xyrem h avallablefor thetreatment Ketamineis commonlymixcd uith 'HE HILI.ORYJ. FARIASAND of nrr.ol.pri. parienGrvho erFeri oitrerdrug\ snch6 ePbedrine,.ai SAMANTHAREID DATE-iAPE enc ePisod.sof .ninplc\1,r nr€di.al PROHIBITIONA(I OF T999 .onditionin Nhicha pc6onsnddcn- ly teels $eak and collapsesat Rohypnol TheHillory J. Farias dd sanrntha nome.is of srbnSemolion. Reid Oate RapePohibition A.t of 1999 was signed into law on Bec.useof touAher.riminalpenalhes F.bruary 13, 20m to nrodify ihe and lai enfor..ncnt cffo.ts thc schedule of the Conbolled aGilabilily of GHB his decreiserl. SubstancesAd (csA) to .rininrl- Abuser hareiunred to GHBanalogs as sub*irutes ize the manliactrre, distributidn, frvo CHB analogs, a,epines !tic[ are depressanh. or possessionof CHB, a desiSner CBL ind BD, aredruSs dral possess wh€n mixedrarh alcohol,Ro\ypnol drug asrc.iaied with date rape chcni.trl in'cturc! closelyEsen .an incipa.itaicvi.tims and ppvent and othei foms of sexualassault bling thnrolcllB GHB anitogs.ft lhenr lrom reshlingassiult. lt .in ayrilable leBallt as industrialsol- produce"amnesia," hhich neins vcnrs.They are aho sold'llegally as individuals mav noi remember Chb dtugs d odo.l6s and @lortess and nay be easily slipFd in[o a drint at a bd or a ?a1ty.Wh€n addedto a dnnk w hout a pe6on's knowledge, th€ drinl may not tasteor l@! ditrerently. Be smdtl PmM yourself by folowing th€se ) Attend partieswith elentsexperienced while underlhe Ictisv hasbecome a populardrug effe.tsofdPdrug. Rohtpnol maybe becauseof th. pcr.cned posihle lethal when mikd * it! al.ohol and effecrsihal a uer e\perienceswitlin an hour of inSesbonAfler lakinS EGt.s\ranindnidurl mavhave feel Rohrpnoli! not approvedfor usenr ingsof nentil stimulatio4en.tidn- the UnitedStatdr .nd its importa- al n armth, enpathl' toward othes, a tion is banned. Illicit lse of acnerrl senseof rvell bein8, and RohypnolbeSan in ihe Llnfiedstates decreasedanxici! Becauseot ihe in theeirh 1990t whcren becane dlugt stimulantproperties, Lhen knoNn as "rophies," loofiet" nscd in dan.eseitings, Ecstasy .an enabldus.B to dancefor exte.ded periods.Howerc! somenFrsepod Abus. of tuo othcr similar dru8s und€sjrableefiects imncdirte\', aPPeasto haveiePla..d Rohy?nol including an\iety, agitation, and abusei. someEgions ofihe counky Thdsear. .lonazcp.m,narkeGd nr theUniled States as Kl.nopin and in Ec{asthasgained. decepriverepu- Mexicoas Rivotril,and alprazolam, tanonasa tate" drug amonguF6. A..ording to the 200.1National Surve! on Drug Use and Health, nore than 10 hillidn peoplehaYe jll5 MDMA kied MDMA at leastonc. lEcsTASYlYet,studies sho{ a druEihat is far Know your limiis! Ove! m frcm harmless lor example,E.stJsy indulging in alohol cn nate can causea dtuSerousindease in the amph€ianinefanily and has bodt tempeEtuie,heait rate and bloodppssure thai lead both stinulant and hallucinogenic can io heart failuie.
Load more

Recommended publications
  • 3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
    Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden.
    [Show full text]
  • Frequently Asked Questions About Synthetic Drugs
    FREQUENTLY ASKED QUESTIONS ABOUT SYNTHETIC DRUGS WHAT ARE SYNTHETIC DRUGS? WHAT DOES THE PACKAGING OF SYNTHETIC CANNABINOIDS LOOK LIKE? A SYNTHETIC DRUG, ALSO REFERRED TO AS A Many of the products are sold in colorful packets with names DESIGNER DRUG, IS A CHEMICAL INTENDED TO that appeal to adolescents and young adults. Manufacturers IMITATE THE PROPERTIES AND EFFECTS OF A label the packages as “not for human consumption” and KNOWN HALLUCINOGEN OR NARCOTIC AND market the products as incense or potpourri to mask the MAY HAVE UNKNOWN SIDE EFFECTS OR CAUSE intended purpose and to avoid regulatory oversight of AN ADVERSE REACTION. THESE DRUGS ARE the manufacturing process. You can view examples of the packaging on page 3. CREATED IN ORDER TO EVADE RESTRICTIONS AGAINST ILLEGAL SUBSTANCES. ARE SYNTHETIC CANNABINOIDS ARE SYNTHETIC DRUGS LEGAL IN TEXAS? DANGEROUS? No. Under state law, it is a crime to manufacture, deliver or Synthetic cannabinoids possess a synthetic drug. are illegal, dangerous, highly addictive and WHAT ARE SYNTHETIC CANNABINOIDS? potentially deadly. One Synthetic cannabinoids are commonly referred to as K2, of the original chemists Kush, Spice, synthetic marijuana and fake weed. They are who designed synthetic a mix of plant matter sprayed with chemicals in sometimes cannabis for research purposes, John Huffman, Ph.D., likened dangerously high proportions, falsely marketed as “legal recreational use of synthetic drugs to playing Russian highs” and smoked like marijuana. roulette. The contents and effects of synthetic cannabinoids WHERE ARE SYNTHETIC CANNABINOIDS SOLD? are unpredictable due to a constantly changing variety of Synthetic cannabinoids are relatively inexpensive and sold chemicals used in manufacturing processes devoid of quality in convenience stores, smoke shops, novelty stores, on the controls and government regulatory oversight.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • Controlled Drug Schedules, Violations & Penalties
    CONTROLLED DRUG SCHEDULES, VIOLATIONS & PENALTIES A REFERENCE FOR THE LAW ENFORCEMENT COMMUNITY April 2015 Prepared by the DEPARTMENT OF CONSUMER PROTECTION Drug Control Division TABLE OF CONTENTS SECTION I CONTROLLED DRUG SCHEDULES & VIOLATIONS An alphabetical listing of controlled drugs by their brand, generic and/or street name that includes each drug’s schedule and the violation(s) from the Connecticut General Statutes (CGS) that are associated with each drug’s sale and/or possession. SECTION II CONTROLLED DRUG VIOLATIONS & PENALTIES A numerical listing of controlled drug violations by their section number in the Connecticut General Statutes (CGS) and the penalty(ies) associated with each violation. SECTION III SUMMARY OF FEDERAL METHAMPHETAMINE STATUTES 2 S E C T I O N I CONTROLLED DRUG SCHEDULES & VIOLATIONS The ‘Schedules of Controlled Substances’ may be found in Sections 21a-243-7 through 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies. www.ct.gov/dcp/lib/dcp/dcp_regulations/21a-243_designation_of_controlled_drugs.pdf 3 Drug State CS Drug Type AKA Sale or Quantity Person Drug- CGS Schedule Possession? Dependent or Not Violation APAP = Acetaminophen APAP = Acetaminophen Drug-Dependent ? ASA = Aspirin ASA = Aspirin “2C-C” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-D” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-E” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-H” Designer Drug - Stimulant “Bath Salts” Federal CS Schedule 1 “2C-I” Designer Drug - Stimulant
    [Show full text]
  • New Psychoactive Substances (NPS): Factsheet
    New psychoactive substances (NPS): factsheet Who is this factsheet for? classified by the Misuse of Drugs Act 1971. This This factsheet is aimed at professionals who do means they are illegal. Possession or supply can not work specifically in the drugs field, but who carry a prison sentence. As new drugs are being may encounter substance misuse as part of developed all the time, it has proved a challenge their role and who need information on current to keep up with them using this law. The UK substance misuse issues. It may also be of government responded to this by bringing in a interest to the general public. new law, the Psychoactive Substances Act 2016. What are ‘new psychoactive This law, which came into effect on 26 May substances’? 2016, covers all psychoactive substances which are NOT already classified under the Misuse of ‘New psychoactive substances’ (NPS) is an Drugs Act 1971. The Psychoactive Substances umbrella term used to cover a wide range of Act 2016 says that possessing with intent to substances with a number of things in common: supply, supplying or offering to supply, producing, importing or exporting any psychoactive • they are psychoactive (they affect the user’s substance, all carry a penalty of up to seven years mental functioning or emotional state by and/or a fine, depending on the seriousness of stimulating or depressing the central nervous the offence. This means that it is against system (brain and spinal cord)); the law to supply anyone with one of these substances. • they are newly available in the UK or have seen a recent increase in popularity and public Possession of a psychoactive substance is not awareness; an offence and carries no penalty.
    [Show full text]
  • Enantioseparation and Determination of Mephedrone and Its Metabolites by Capillary Electrophoresis Using Cyclodextrins As Chiral Selectors
    molecules Article Enantioseparation and Determination of Mephedrone and Its Metabolites by Capillary Electrophoresis Using Cyclodextrins as Chiral Selectors Pavel Rezankaˇ 1,* , Denisa Macková 1, Radek Jurok 2,3, Michal Himl 3 and Martin Kuchaˇr 2 1 Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic; [email protected] 2 Department of Chemistry of Natural Compounds, Forensic Laboratory of Biologically Active Substances, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic; [email protected] (R.J.); [email protected] (M.K.) 3 Department of Organic Chemistry, Faculty of Chemical Technology, University of Chemistry and Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic; [email protected] * Correspondence: [email protected] Academic Editor: Estrella Núñez Delicado Received: 25 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: Mephedrone, a psychoactive compound derived from cathinone, is widely used as a designer drug. The determination of mephedrone and its metabolites is important for understanding its possible use in medicine. In this work, a method of capillary electrophoresis for the chiral separation of mephedrone and its metabolites was developed. Carboxymethylated β-cyclodextrin was selected as the most effective chiral selector from seven tested cyclodextrin derivates. Based on the simplex method, the optimal composition of the background electrolyte was determined: at pH 2.75 and 7.5 mmol L 1 carboxymethylated β-cyclodextrin the highest total resolution of a mixture of analytes · − was achieved. For mephedrone and its metabolites, calibration curves were constructed in a calibration range from 0.2 to 5 mmol L 1; limits of detection, limits of quantification, precision, and repeatability · − were calculated, and according to Mandel’s fitting test, the linear calibration ranges were determined.
    [Show full text]
  • The Designer Methcathinone Analogs, Mephedrone and Methylone, Are Substrates for Monoamine Transporters in Brain Tissue
    Neuropsychopharmacology (2012) 37, 1192–1203 & 2012 American College of Neuropsychopharmacology. All rights reserved 0893-133X/12 www.neuropsychopharmacology.org The Designer Methcathinone Analogs, Mephedrone and Methylone, are Substrates for Monoamine Transporters in Brain Tissue ,1 1 1 1 2 Michael H Baumann* , Mario A Ayestas Jr , John S Partilla , Jacqueline R Sink , Alexander T Shulgin , 2 3 1 4 5 Paul F Daley , Simon D Brandt , Richard B Rothman , Arnold E Ruoho and Nicholas V Cozzi 1 Translational Pharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, 2 3 MD, USA; Alexander Shulgin Research Institute, Lafayette, CA, USA; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores 4 University, Liverpool, UK; Department of Neuroscience and the UW Eye Research Institute, University of Wisconsin School of Medicine and 5 Public Health, Madison, WI, USA; Neuropharmacology Laboratory, Department of Cell and Regenerative Biology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA The nonmedical use of ‘designer’ cathinone analogs, such as 4-methylmethcathinone (mephedrone) and 3,4-methylenedioxymethcathi- none (methylone), is increasing worldwide, yet little information is available regarding the mechanism of action for these drugs. Here, we employed in vitro and in vivo methods to compare neurobiological effects of mephedrone and methylone with those produced by the structurally related compounds, 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine. In vitro release assays using rat brain synaptosomes revealed that mephedrone and methylone are nonselective substrates for plasma membrane monoamine transporters, similar to MDMA in potency and selectivity. In vivo microdialysis in rat nucleus accumbens showed that i.v.
    [Show full text]
  • Drugs and New Potentially Dangerous Chemical Substances, with a Brief Review of the Problem
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL & SCIENCE EDUCATION 2016, VOL. 11, NO. 14, 6697-6703 OPEN ACCESS Approach to Classifying “Design” Drugs and New Potentially Dangerous Chemical Substances, With a Brief Review of the Problem Azat R. Asadullina, Elena Kh. Galeevab, Elvina A. Achmetovaa and Ivan V. Nikolaevb aBashkir State Medical University of the Ministry of Health of the Russian Federation, Ufa, RUSSIA; bRepublican Narcological Dispensary No.1 of the Ministry of Health of the Republic of Bashkortostan, Ufa, RUSSIA ABSTRACT The urgency of this study has become vivid in the light of the growing problem of prevalence and bBPHFuse Republican of new synthetic Narcological drug types. DispensaryLately there has No.1 been of a thetendency Ministry of expanding of Health the rangeof the of psychologically active substances (PAS) used by addicts with the purpose of their illegal taking. RepublicThe aim of Bashkortostan,of this research is anPushkin attempt str.,of systematizing 119/1, Ufa, and RB. classifying “design” drugs according to their chemical structure, neurochemical mechanisms of action and clinical manifestations. As a result, we have found that they can be divided into ten big groups. This classification will allow to better arrange new clinical phenomenology in modern addictology. This paper would be useful for psychiatrists, experts in narcology, as well as for personnel of institutions and agencies engaged in anti-drug activity. KEYWORDS ARTICLE HISTORY Opiates, cannabinoids, cathinones, tryptamine, Received 20 April 2016 cocaine, pregabalin, new “design” drugs, Revised 28 May 2016 classification Accepted 29 Мау 2016 Introduction Urgency of the problem Recently, the sphere of illegal turnover of narcotic substances has shown an apparent trend of producing the so-called “design drugs” (DN): new potentially dangerous psychologically active substances (NPDPAS) obtained by means of chemical synthesis, possessing a high narcotic effect and manufactured with the CORRESPONDENCE Azat R.
    [Show full text]
  • Bath Salt-Type Aminoketone Designer Drugs: Analytical and Synthetic Studies on Substituted Cathinones
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Bath Salt-type Aminoketone Designer Drugs: Analytical and Synthetic Studies on Substituted Cathinones Author(s): Randall Clark, Ph.D. Document No.: 250125 Date Received: July 2016 Award Number: 2013-DN-BX-K022 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this federally funded grant report available electronically. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. Final Summary Overview, NIJ award 2013-DN-BX-K022 Bath Salt-type Aminoketone Designer Drugs: Analytical and Synthetic Studies on Substituted Cathinones Purpose of Project: This project has focused on issues of resolution and discriminatory capabilities in controlled substance analysis providing data to increase reliability and selectivity for forensic evidence and analytical data on new analytes of the so-called bath salt-type drugs of abuse. The overall goal of these studies is to provide an analytical framework for the identification of individual substituted cathinones to the exclusion of all other possible isomeric and homologous forms of these compounds. A number of aminoketones or beta-keto/benzylketo compounds (bk-amines) have appeared on the illicit drug market in recent years including methcathinone, mephedrone, methylone and MDPV (3,4-methylenedioxypyrovalerone). These substances represent a variety of aromatic ring substituent, hydrocarbon side chain and amino group modifications of the basic cathinone/methcathinone molecular skeleton.
    [Show full text]
  • Mephedrone Monograph
    SOFT Designer Drug Committee Monographs vers. 1.1 9/13/2013 Emerging Designer Drug Monograph Revision Date: July 22, 2013 Author(s): Elizabeth Schlatter, Barry K. Logan Drug Name: Mephedrone Synonyms: 4-Methylmethcathinone, 4-MeMC, 4-Methylephedrone, 4-MMC, 2-aminomethyl-1- tolyl-propan- 1-one Structure: O CH3 HN H3C CH 3 Formula: C11H15NO Molecular Weight: 177.2 Pharmacological Drug Class: CNS Stimulant that initiates catecholamine release and inhibits monoamine oxidase, increasing concentrations of serotonin, norepinephrine, and dopamine in the synaptic cleft (1). Metabolism: Mephedrone is N-demethylated to a primary amine metabolite. Ketone groups are reduced to alcohols (1). Blood Concentrations: Case studies outlined by Maskell et al (2011) report plasma mephedrone concentrations of 0.15mg/L in a non-fatal intoxication. In a case involving multiple drug toxicity mephedrone blood concentration was 0.5mg/L (2,3). Adamowicz (2013) reports fatal mephedrone concentrations range of 5.5 µg/mL in the blood and 7.1 µg/mL in the vitreous humor (4). Effects and Toxicity: Mephedrone is a synthetic cathinone derivative that has stimulant effects similar to methamphetamine, ecstasy, and cocaine (3). Effects include increased alertness, tachycardia, sweating, and insomnia (5). Additionally, users describe feelings of empathy and euphoria (see www.erowid.org). Analysis: Mephedrone is a small, basic drug that chromatographs well through GC-MS. See SWGDRUG Monograph for GC-MS method and sample chromatographs. Dickson et al (2010) collected data at a mass range if 42-550, using a SIM method targeting m/z 204, 160, 119. Extractions and GC-MS method parameters are outlined (3).
    [Show full text]
  • Designer Drugs Are Prohibited in the Visa Payments System AP, Canada, CEMEA, Europe, LAC, U.S
    Systems & Operations | Visa Rules 4 May 2017 Designer Drugs Are Prohibited in the Visa Payments System AP, Canada, CEMEA, Europe, LAC, U.S. | Acquirers, Issuers, Processors, Agents Overview: Acquirers must comply with Visa’s updated rules that prohibit merchants from accepting Visa cards for the purchase of designer drugs. Effective 1 October 2017, Visa will begin identifying acquirers with merchants that sell designer drugs; Visa may penalize those acquirers via the Global Brand Protection Program. Best practices for identifying rogue merchants selling these products are provided. Designer drugs are synthetic, chemical analogs of controlled substances, intended Mark Your Calendar: to imitate their psychoactive effects. The resulting products are structurally similar (often within one or two molecules) to illegal psychoactive drugs. Often marketed • Acquirers must comply with as street drug alternatives or as “legal” highs, designer drugs typically result in new rules that prohibit hallucinogenic, stimulative or opioid-like effects for the users. designer drugs in the Visa system (1 July 2017) In response to the growing threat of designer drugs to public health and safety, • GBPP enforcement of and to the Visa brand, Visa updated its rules effective 30 March 2017 to prohibit prohibited merchants take the use of Visa cards to purchase designer drugs. Acquirers must: effect (1 October 2017) Ensure that a Merchant, Payment Facilitator, Sponsored Merchant, or Staged Related Training From Digital Wallet Operator does not accept Visa Cards for, or display a Visa- Visa Business School: Owned Mark on a website that is used in relation to products that claim or • Fraud and Risk imply a similar efficacy as prescription drugs, controlled substances, or recreational / street drugs, irrespective of claims of legality or any other media or activities (ID#s: 0026379, 0005067, 0008355).
    [Show full text]
  • Designer Drugs & Treatment Implications
    Designer Drugs & Treatment Implications: Will They Turn You into a Zombie? What Treatment Providers Need to Know about Synthetic Drugs Vicki Staples, MEd, CPRP ASU Center for Applied Behavioral Health Policy /Pacific Southwest ATTC 10th Annual Phoenix Area Integrated Behavioral Health Training- Phoenix, AZ Curriculum Development Collaborators • Gulf Coast Addiction Technology Transfer Center –University of Texas, School of Social Work • Pacific Southwest Addiction Technology Transfer Center –UCLA Integrated Substance Abuse Programs 2 Special Acknowledgements • Dr. Volker Auwaerter, University Medical Center Freiburg, Germany • Dr. Michael Bauman, Intramural Research Program, NIDA • Dr. Raimondo Bruno, University of Tasmania • Mathias Forrester, Texas Department of State Health Services • Dr. Paul Griffiths, EMCDDA • James Hall, Nova Southeastern University • Dr. Barry Logan, National Medical Services Labs, Inc. 3 What do you think? 4 Educational Objectives At the end of this presentation, participants will be able to: 1. Identify the key characteristics and effects of synthetic drugs, most notably synthetic cannabinoids and synthetic cathinones. 2. Describe the current information available on the availability and patterns of synthetic drug use in the United States. 3. Explain strategies for communicating the dangers involved with synthetic drug use. 5 “Tales of Bath Salts and Zombie Cannibalism” • Bath Salts made headlines in summer 2012 when a story of possible cannibalism was reported in Miami, FL • The Miami-Dade Medical Examiner
    [Show full text]